I read with interest the case report entitled “Arthritis and myositis in a patient with programmed cell death-1 (PD-1) inhibitor pembrolizumab for lung cancer”, recently published in the Mediterranean Journal of Rheumatology.1 This evidence concerns the gene PDCD1 and myositis disease.